TLSA stock icon

Tiziana Life Sciences


Market Cap: 82.2M


About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Employees: 9

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

0.02% more ownership

Funds ownership: 0.78% [Q4 2023] → 0.8% (+0.02%) [Q1 2024]

5% less funds holding

Funds holding: 21 [Q4 2023] → 20 (-1) [Q1 2024]

16% less capital invested

Capital invested by funds: $444K [Q4 2023] → $374K (-$69.8K) [Q1 2024]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Research analyst outlook

We haven’t received any recent analyst ratings for TLSA.

Financial journalist opinion

Based on 4 articles about TLSA published over the past 30 days